Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
05 2019
Historique:
received: 02 07 2018
revised: 14 01 2019
accepted: 09 02 2019
entrez: 22 4 2019
pubmed: 22 4 2019
medline: 28 3 2020
Statut: ppublish

Résumé

To investigate the patterns of nodal failure in patients enrolled in the international multicentre EMBRACE study. Nodal disease at diagnosis (N-, N+) and nodal failure were analysed per region (NF) (pelvic (parametrial, common iliac, internal/external iliac), inguinal and para-aortic (PAO)) in 1338 patients. Treatment consisted of chemo-radiation and MRI guided brachytherapy. PAO radiotherapy and/or nodal boost was left to the treating centre. At time of diagnosis 52% of patients had pathologic nodes. Frequency analyses were performed in relation to patient, primary tumour and nodal disease characteristics, and treatment related factors. Median follow up was 34 months and 83% of NF occurred within 24 months. At diagnosis 99% of the N+ patients had pathologic nodes in the pelvis and 14% in the PAO. NF Within the EMBRACE study cohort the overall number of patients developing nodal failure is low, significantly lower for N- compared to N+ patients. Pathological nodes at diagnosis are mainly located in the pelvis, whereas nodal failures are more often reported in the PAO region. About 40% of all nodal failures were reported outside the treatment targets.

Identifiants

pubmed: 31005214
pii: S0167-8140(19)30074-X
doi: 10.1016/j.radonc.2019.02.007
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

185-190

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Christel N Nomden (CN)

Department of Radiation Oncology, University Medical Center Utrecht, the Netherlands.

Richard Pötter (R)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.

Astrid A C de Leeuw (AAC)

Department of Radiation Oncology, University Medical Center Utrecht, the Netherlands.

Kari Tanderup (K)

Department of Oncology, Aarhus University Hospital, Denmark.

Jacob C Lindegaard (JC)

Department of Oncology, Aarhus University Hospital, Denmark.

Maximilian P Schmid (MP)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.

Israël Fortin (I)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.

Christine Haie-Meder (C)

Department of Radiation Oncology, Gustave Roussy, Villejuif, France.

Umesh Mahantshetty (U)

Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Homi Bhabha National Institute (HBNI), India.

Peter Hoskin (P)

Cancer Centre, Mount Vernon Hospital, Northwood, United Kingdom.

Barbara Segedin (B)

Department of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia.

Kjersti Bruheim (K)

Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Norway.

Bhavana Rai (B)

Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Fleur Huang (F)

Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, Canada.

Rachel Cooper (R)

Leeds Cancer Centre, St James's University Hospital, United Kingdom.

Elzbieta Van Der Steen Banasik (E)

Department of Radiotherapy, Arnhem, the Netherlands.

Erik Van Limbergen (E)

Department of Radiation Oncology, UZ Leuven, Belgium.

Ina M Jürgenliemk-Schulz (IM)

Department of Radiation Oncology, University Medical Center Utrecht, the Netherlands. Electronic address: I.M.Schulz@umcutrecht.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH